针对癌症向治疗的抗PD-L1免疫毒素的开发和表征
Ali Takhteh1,2, Mohammad Hosseininejad-Chafi1, Akbar Oghalaie1
1Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Current pharmaceutical biotechnology
|September 6, 2024
概括
一种新型的免疫毒素 (IT) 针对编程细胞死亡利干-1 (PD-L1) 已通过将抗PD-L1纳米体 (Nb) 与截断的甲状腺毒素 (DT) 融合而成功构建. 这种IT证明了强大的癌细胞细胞毒性,显示了癌症免疫治疗的前景.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 免疫毒素 (IT) 是设计用于向细胞破坏的双功能治疗药物.
- 编程细胞死亡利干-1 (PD-L1) 是一种在各种癌症中过度表达的蛋白质.
研究的目的:
- 通过将抗PD-L1纳米体 (Nb) 基因融合到截断的白喉毒素 (DT) 来构建一种新型免疫毒素.
主要方法:
- 抗PD-L1 Nb和截断的DT的基因融合.
- 使用分子克隆和染色学来表达和净化IT.
- 通过SDS-PAGE,西斑,ELISA和MTT测试进行验证.
主要成果:
- 构建的IT有效地绑定到PD-L1.1.
- 实验室对表达PD-L1的癌细胞 (A-431) 具有显著的细胞毒性.
- 截断的DT单独显示没有结合活性.
结论:
- 新型抗PD-L1 IT的特征很好,并显示出治疗潜力.
- 需要进一步研究这种IT在癌症免疫治疗中的有效性和安全性.
更多相关视频
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
254
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
